23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › KalVista Pharmaceuticals, Inc. › 2025-2026

KalVista Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and KalVista Pharmaceuticals, Inc.’s Form 8-K, filed October 2, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 167Asset managers, any item
  • 640Fund votes
  • October 1, 2025Meeting date

Results at a glance

Meeting of October 1, 2025: 4 items on KalVista Pharmaceuticals, Inc.’s Form 8-K, filed October 2, 2025: 4 passed (calculated).

Dissent

Notable dissent: 1 director (19.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KalVista Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by KalVista Pharmaceuticals, Inc.

These tallies are KalVista Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed October 2, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KalVista Pharmaceuticals, Inc. — official shareholder meeting results, meeting held October 1, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Benjamin L. Palleiko 36,096,8041,491,8763,100 --3,882,274 96%Passed (calculated)—
Elect Director: Brian J.G. Pereira 30,303,7287,284,9413,111 --3,882,274 81%Passed (calculated)—
2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the eight-month transition period ending December 31, 2025 41,421,54844,4178,089 --0 99.9%Passed (calculated)—
3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers 33,600,8083,985,8605,112 --3,882,274 89%Passed (calculated)—

Source: KalVista Pharmaceuticals, Inc., Form 8-K, filed with the SEC on October 2, 2025 — read the filing on EDGAR.

How asset managers voted at the KalVista Pharmaceuticals, Inc. 2025-2026 meeting

167 asset managers disclosed a vote on at least one KalVista Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Benjamin L. Palleiko

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 36,096,804AGAINST: 1,491,876
Details: description as filed, official tally, votes by 43 asset managers

Description as filed by funds: The election of two Class I directors to hold office until the earliest of our 2028 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: Benjamin L. Palleiko

KalVista Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Benjamin L. Palleiko”): 36,096,804 for, 1,491,876 against, per its Form 8-K filed October 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 7,652,382 for, 905,786 against.

FOR
FOR: 7,652,382AGAINST: 905,786
Largest asset managers voting on “The election of two Class I directors to hold office until the earliest of our 2028 annual meeting of stockhol” at KalVista Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group3,177,5870 00For
Vanguard2,116,2690 00For
BlackRock1,071,6980 00For
RBB FUND, INC.0601,685 00Against
Principal1,691286,670 00Against
Fidelity275,4640 00For
BNY Mellon215,8420 00For
Charles Schwab113,4540 00For
Equitable95,0080 00For
CARILLON SERIES TRUST78,8580 00For
TIAA67,9770 00For
QUANTITATIVE MASTER SERIES LLC61,5000 00For
Russell Investments52,9390 00For
Direxion Shares ETF Trust50,2050 00For
State Street41,6760 00For
Northern Trust30,7940 00For
Lincoln Financial29,2000 00For
ProShares19,8630 00For
AIG/SunAmerica19,2360 00For
Global X19,0290 00For
Dimensional017,431 00Against
John Hancock14,5740 00For
Invesco14,0680 00For
Pacific Life11,9180 00For
Nationwide11,4310 00For

Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).

Elect Director: Brian J.G. Pereira

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%AGAINST
FOR: 30,303,728AGAINST: 7,284,941
Details: description as filed, official tally, votes by 43 asset managers

Description as filed by funds: The election of two Class I directors to hold office until the earliest of our 2028 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: Brian J.G. Pereira

KalVista Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Brian J.G. Pereira”): 30,303,728 for, 7,284,941 against, per its Form 8-K filed October 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 7,137,096 for, 1,421,072 against.

FORAGAINST
FOR: 7,137,096AGAINST: 1,421,072
Largest asset managers voting on “The election of two Class I directors to hold office until the earliest of our 2028 annual meeting of stockhol” at KalVista Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group3,177,5870 00For
Vanguard2,116,2690 00For
BlackRock1,071,6980 00For
RBB FUND, INC.0601,685 00Against
Principal0288,361 00Against
Fidelity275,4640 00For
BNY Mellon215,8420 00For
Charles Schwab113,4540 00For
Equitable68,39826,610 00Mixed
CARILLON SERIES TRUST078,858 00Against
TIAA067,977 00Against
QUANTITATIVE MASTER SERIES LLC61,5000 00For
Russell Investments052,939 00Against
Direxion Shares ETF Trust050,205 00Against
State Street6741,609 00Against
Northern Trust030,794 00Against
Lincoln Financial029,200 00Against
ProShares019,863 00Against
AIG/SunAmerica019,236 00Against
Global X019,029 00Against
Dimensional017,431 00Against
John Hancock014,574 00Against
Invesco014,068 00Against
Pacific Life11,9180 00For
Nationwide11,4310 00For

Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).

Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 8 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 33,600,808AGAINST: 3,985,860

Prior year: 85.6% for (October 3, 2024 meeting) ▲ 3.8 pts

Details: description as filed, official tally, votes by 166 asset managers

Description as filed by funds: Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.

KalVista Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers”): 33,600,808 for, 3,985,860 against, per its Form 8-K filed October 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 43 asset managers voting on “Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as d” at KalVista Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group03,177,587 00Against
Vanguard2,116,2690 00For
BlackRock1,071,6980 00For
RBB FUND, INC.601,6850 00For
Principal288,3610 00For
Fidelity275,4640 00For
BNY Mellon215,8420 00For
Charles Schwab113,4540 00For
Equitable95,0080 00For
CARILLON SERIES TRUST78,8580 00For
TIAA67,9770 00For
QUANTITATIVE MASTER SERIES LLC61,5000 00For
Russell Investments52,9390 00For
Direxion Shares ETF Trust50,2050 00For
State Street41,66115 00For
Northern Trust30,7940 00For
Lincoln Financial29,2000 00For
ProShares19,8630 00For
AIG/SunAmerica19,2360 00For
Global X19,0290 00For
Dimensional17,4310 00For
John Hancock14,5740 00For
Invesco014,068 00Against
Pacific Life11,9180 00For
Nationwide11,4310 00For

Fund voting reports, all 43 managers: 5,362,767 for, 3,195,401 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 137 asset managers voting on “Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as d” at KalVista Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Venrock Adviser, LLC6,728,9850 00For
MONTANOVA CAPITAL, LLC4,768,7120 00For
Capital Group03,177,587 00Against
Vestal Point Capital, LP1,296,2350 00For
BlackRock1,230,62420,039 00For
Octagon Capital Advisors LP1,068,4960 00For
SILVERARC CAPITAL MANAGEMENT, LLC951,1120 00For
EMERALD MUTUAL FUND ADVISERS TRUST888,3550 00For
EMERALD ADVISERS, LLC505,4380 00For
State Street496,895121 00For
DAFNA Capital Management LLC444,7310 00For
GEODE CAPITAL MANAGEMENT, LLC353,4250 00For
Newton Investment Management North America, LLC340,1450 00For
AMERIPRISE FINANCIAL INC316,0950 00For
Northern Trust226,1910 00For
NAN FUNG TRINITY (HK) Ltd154,5220 00For
PANAGORA ASSET MANAGEMENT INC149,5070 00For
Charles Schwab113,5310 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC113,1710 00For
Vanguard102,7820 00For
Goldman Sachs95,8380 00For
Wellington90,8520 00For
MELLON INVESTMENTS Corp082,383 00Against
Nuveen79,7580 00For
NEXTBio Capital Management LP65,8960 00For

Institutional-manager reports, all 137 managers: 21,414,014 for, 3,371,738 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 41,421,548AGAINST: 44,417

Prior year: 99.9% for (October 3, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 43 asset managers

Description as filed by funds: THE RATIFICATION OF THE SELECTION BY THE AUDIT COMMITTEE OF OUR BOARD, OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR EIGHT-MONTH TRANSITION PERIOD ENDING DECEMBER 31, 2025.

KalVista Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the eight-month transition period ending December 31, 2025”): 41,421,548 for, 44,417 against, per its Form 8-K filed October 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 8,558,166 for, 2 against.

FOR
FOR: 8,558,166AGAINST: 2
Largest asset managers voting on “THE RATIFICATION OF THE SELECTION BY THE AUDIT COMMITTEE OF OUR BOARD, OF DELOITTE & TOUCHE LLP AS OUR INDEPEN” at KalVista Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group3,177,5870 00For
Vanguard2,116,2690 00For
BlackRock1,071,6980 00For
RBB FUND, INC.601,6850 00For
Principal288,3610 00For
Fidelity275,4640 00For
BNY Mellon215,8420 00For
Charles Schwab113,4540 00For
Equitable95,0080 00For
CARILLON SERIES TRUST78,8580 00For
TIAA67,9770 00For
QUANTITATIVE MASTER SERIES LLC61,5000 00For
Russell Investments52,9390 00For
Direxion Shares ETF Trust50,2050 00For
State Street41,6742 00For
Northern Trust30,7940 00For
Lincoln Financial29,2000 00For
ProShares19,8630 00For
AIG/SunAmerica19,2360 00For
Global X19,0290 00For
Dimensional17,4310 00For
John Hancock14,5740 00For
Invesco14,0680 00For
Pacific Life11,9180 00For
Nationwide11,4310 00For

Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).

Largest KalVista Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 43,215,472 shares outstanding at the time of that meeting.

Fund voting reports: top KalVista Pharmaceuticals, Inc. shareholders by shares voted on “Approval, on a non-binding advisory basis, of the compensation paid by us to our named…”, 2025-2026
#Asset manager % of shares outstanding
1Capital Group 7.35%
2Vanguard 4.90%
3BlackRock 2.48%
4RBB FUND, INC. 1.39%
5Principal 0.67%
6Fidelity 0.64%
7BNY Mellon 0.50%
8Charles Schwab 0.26%
9Equitable 0.22%
10CARILLON SERIES TRUST 0.18%
Institutional-manager reports: top KalVista Pharmaceuticals, Inc. shareholders by shares voted on “Approval, on a non-binding advisory basis, of the compensation paid by us to our named…”, 2025-2026
#Asset manager % of shares outstanding
1Venrock Adviser, LLC 15.57%
2MONTANOVA CAPITAL, LLC 11.03%
3Capital Group 7.35%
4Vestal Point Capital, LP 3.00%
5BlackRock 2.89%
6Octagon Capital Advisors LP 2.47%
7SILVERARC CAPITAL MANAGEMENT, LLC 2.20%
8EMERALD MUTUAL FUND ADVISERS TRUST 2.06%
9EMERALD ADVISERS, LLC 1.17%
10State Street 1.15%

Reported KalVista Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

KalVista Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with Venrock Healthcare Capital Partners III, L.P.5,012,796 11.60%Proxy statement (DEF 14A), table as of August 6, 2025
Tang Capital Partners, LP4,941,798 11.44%Proxy statement (DEF 14A), table as of August 6, 2025
Entities affiliated with Frazier Life Sciences Public Fund, L.P.4,887,867 11.31%Proxy statement (DEF 14A), table as of August 6, 2025
Entities affiliated with Suvretta Capital Management, LLC4,328,904 10.02%Proxy statement (DEF 14A), table as of August 6, 2025
Vestal Point Capital, L.P.4,000,000 9.26%Proxy statement (DEF 14A), table as of August 6, 2025
BlackRock3,795,897 8.78%Form 13F, quarter ended March 31, 2026
Capital World Investors3,177,587 7.35%Proxy statement (DEF 14A), table as of August 6, 2025
Vanguard Group2,509,020 5.81%Form 13F, quarter ended March 31, 2026
Point722,136,940 4.94%Form 13F, quarter ended March 31, 2026
State Street1,955,844 4.53%Form 13F, quarter ended March 31, 2026

Percentages above are of 43,215,472 shares outstanding, as reported by KalVista Pharmaceuticals, Inc. on its Form 10-Q dated August 26, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At KalVista Pharmaceuticals, Inc.'s shareholder meeting held October 1, 2025, in the 2025-2026 proxy season, 167 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 640 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding advisory basis, of the compensation paid by us to our named… — FOR was 89% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KalVista Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on October 2, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KalVista Pharmaceuticals, Inc.’s 10-Q dated August 26, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

KalVista Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “KalVista Pharmaceuticals, Inc. 2025 Annual Meeting (2025-2026 season)”, https://proxyvotesnow.com/company/kalvista-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.